title: Microthrombosis after experimental subarachnoid hemorrhage: time course and effect of red blood cell-bound thrombin-activated pro-urokinase and clazosentan.
abstract: Delayed cerebral ischemia (DCI) is a significant cause of morbidity and mortality for patients surviving the rupture of an intracranial aneurysm. Despite an association between vasospasm and DCI, thrombosis and thromboembolism may also contribute to DCI. In this study we investigate the time course of intravascular microclot formation after experimental subarachnoid hemorrhage (SAH) and assess the effects of the following two drugs on microclot burden: mutant thrombin-activated urokinase-type plasminogen activator (scFv/uPA-T), which is bound to red blood cells for use as a thromboprophylactic agent, and clazosentan, an endothelin antagonist. In the first study, adult male C57BL/6 mice were sacrificed at 24 (n=5), 48 (n=6), 72 (n=8), and 96 (n=3) hours after SAH induced by filament perforation of the anterior cerebral artery. Sham animals (n=5) underwent filament insertion without puncture. In the second study, animals received scFv/uPA-T (n=5) 3 hours after hemorrhage, clazosentan (n=5) by bolus and subcutaneous pump after SAH just prior to skin closure, or a combination of scFv/uPA-T and clazosentan (n=4). Control (n=6) and sham (n=5) animals received saline alone. All animals were sacrificed at 48 hours and underwent intra-cardiac perfusion with 4% paraformaldehyde. The brains were then extracted and sliced coronally on a cryostat and processed for immunohistochemistry. An antibody recognizing thrombin-anti-thrombin complexes was used to detect microclots on coronal slices. Microclot burden was calculated for each animal and compared among groups. Following SAH, positive anti-thrombin staining was detected bilaterally in the following brain regions, in order of decreasing frequency: cortex; hippocampus; hypothalamus; basal ganglia. Few microclots were found in the shams. Microclot burden peaked at 48 hours and then decreased gradually. Animals receiving scFv/uPA-T and scFv/uPA-T+clazosentan had a lower microclot burden than controls, whereas animals receiving clazosentan alone had a higher microclot burden (p<0.005). The overall mortality rate in the time course study was 40%; mortality was highest among control animals in the second study. Intravascular microclots form in a delayed fashion after experimental SAH. Microclots may be safely reduced using a novel form of thromboprophylaxis provided by RBC-targeted scFv/uPA-T and represent a potential target for therapeutic intervention in the treatment of DCI.
authors.affiliation: Department of Neurosurgery, Hospital of the University of Pennsylvania, Philadelphia, PA 19104, USA.
authors.forename: Jared M
authors.initials: JM
authors.lastname: Pisapia
authors.forename: Xiangsheng
authors.initials: X
authors.lastname: Xu
authors.forename: Jane
authors.initials: J
authors.lastname: Kelly
authors.forename: Jamie
authors.initials: J
authors.lastname: Yeung
authors.forename: Geneive
authors.initials: G
authors.lastname: Carrion
authors.forename: Huaiyu
authors.initials: H
authors.lastname: Tong
authors.forename: Sudha
authors.initials: S
authors.lastname: Meghan
authors.forename: Omar M
authors.initials: OM
authors.lastname: El-Falaky
authors.forename: M Sean
authors.initials: MS
authors.lastname: Grady
authors.forename: Douglas H
authors.initials: DH
authors.lastname: Smith
authors.forename: Sergei
authors.initials: S
authors.lastname: Zaitsev
authors.forename: Vladimir R
authors.initials: VR
authors.lastname: Muzykantov
authors.forename: Michael F
authors.initials: MF
authors.lastname: Stiefel
authors.forename: Sherman C
authors.initials: SC
authors.lastname: Stein
mesh_terms: D000704:Analysis of Variance; D000818:Animals; D002536:Cerebral Arteries; D004146:Dioxanes / Q000627:therapeutic use*; D004195:Disease Models, Animal; D018450:Disease Progression; D016503:Drug Delivery Systems; D004912:Erythrocytes / Q000502:physiology; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006021:Glycophorins / Q000378:metabolism; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D011725:Pyridines / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D013345:Subarachnoid Hemorrhage / Q000150:complications; D013449:Sulfonamides / Q000627:therapeutic use*; D013777:Tetrazoles / Q000627:therapeutic use*; D013927:Thrombosis / Q000209:etiology / Q000517:prevention & control*; D013997:Time Factors; D014568:Urokinase-Type Plasminogen Activator / Q000627:therapeutic use*
chemical_list: D004146:Dioxanes; D005343:Fibrinolytic Agents; D006021:Glycophorins; D011725:Pyridines; D011743:Pyrimidines; D013449:Sulfonamides; D013777:Tetrazoles; C109641:clazosentan; D014568:Urokinase-Type Plasminogen Activator
references.citation: Neurology. 1986 Mar;36(3):329-33
references.pmid: 3951698
references.citation: J Neurosurg. 2003 May;98(5):978-84
references.pmid: 12744357
references.citation: J Neurol Neurosurg Psychiatry. 1995 Oct;59(4):451-2
references.pmid: 7561935
references.citation: J Neurosurg. 1988 Apr;68(4):505-17
references.pmid: 3280746
references.citation: AJNR Am J Neuroradiol. 2001 Jun-Jul;22(6):1143-8
references.pmid: 11415911
references.citation: Stroke. 2002 Sep;33(9):2317-23
references.pmid: 12215605
references.citation: N Engl J Med. 1983 Mar 17;308(11):619-24
references.pmid: 6338383
references.citation: Neurosurgery. 2006 Oct;59(4):781-7; discussion 787-8
references.pmid: 16915120
references.citation: Neurosurgery. 2002 May;50(5):1026-30; discussion 1030-1
references.pmid: 11950405
references.citation: Neurosurg Focus. 2006 Sep 15;21(3):E1
references.pmid: 17029333
references.citation: J Neurosurg. 1991 Mar;74(3):386-92
references.pmid: 1993903
references.citation: Discov Med. 2003 Oct;3(18):28-9
references.pmid: 20704855
references.citation: Neurology. 1998 Apr;50(4):876-83
references.pmid: 9566366
references.citation: J Cereb Blood Flow Metab. 2008 Nov;28(11):1761-70
references.pmid: 18628782
references.citation: J Pharmacol Exp Ther. 1997 Dec;283(3):1110-8
references.pmid: 9399983
references.citation: Neurol Res. 2002 Jul;24(5):510-6
references.pmid: 12117325
references.citation: Cochrane Database Syst Rev. 2003;(2):CD001245
references.pmid: 12804399
references.citation: Neurosurgery. 2004 Feb;54(2):326-34; discussion 334-5
references.pmid: 14744278
references.citation: Clin Neurol Neurosurg. 2004 Mar;106(2):97-103
references.pmid: 15003298
references.citation: Acta Neurochir (Wien). 1990;102(1-2):1-10
references.pmid: 2407050
references.citation: J Neurosurg. 1997 Aug;87(2):207-14
references.pmid: 9254083
references.citation: Nat Clin Pract Neurol. 2007 May;3(5):256-63
references.pmid: 17479073
references.citation: Brain. 1964 Sep;87:491-510
references.pmid: 14215175
references.citation: Acta Neurochir (Wien). 1994;131(1-2):137-45
references.pmid: 7709776
references.citation: Neurosurgery. 2003 May;52(5):1017-22; discussion 1022-4
references.pmid: 12699542
references.citation: J Neurosurg. 2005 Jul;103(1):9-17
references.pmid: 16121967
references.citation: Ann Clin Lab Sci. 2010 Winter;40(1):32-42
references.pmid: 20124328
references.citation: J Pharmacol Exp Ther. 2010 Mar;332(3):1022-31
references.pmid: 19952305
references.citation: Neurosurg Focus. 2006 Sep 15;21(3):E2
references.pmid: 17029341
references.citation: Cochrane Database Syst Rev. 2005 Jan 25;(1):CD000277
references.pmid: 15674871
references.citation: J Neuroimaging. 2008 Oct;18(4):396-401
references.pmid: 18494776
references.citation: Neurosurg Focus. 2006 Sep 15;21(3):E4
references.pmid: 17029343
references.citation: Neurochem Res. 1997 Oct;22(10):1249-55
references.pmid: 9342729
references.citation: Neurosurgery. 2009 Mar;64(3):546-53; discussion 553-4
references.pmid: 19240618
references.citation: Stroke. 2001 Aug;32(8):1860-2
references.pmid: 11486117
references.citation: Stroke. 2000 Jul;31(7):1621-7
references.pmid: 10884463
references.citation: Circulation. 2004 Jun 8;109(22):2698-704
references.pmid: 15184294
references.citation: J Neurosurg. 2004 Nov;101(5):813-21
references.pmid: 15540920
references.citation: Acta Neurochir (Wien). 1998;140(6):579-84
references.pmid: 9755325
references.citation: Stroke. 2005 May;36(5):992-7
references.pmid: 15831836
references.citation: Neurosurgery. 1998 Mar;42(3):490-3; discussion 493-4
references.pmid: 9526982
references.citation: J Neurol Neurosurg Psychiatry. 2000 Mar;68(3):337-41
references.pmid: 10675216
references.citation: Nat Biotechnol. 2003 Aug;21(8):891-6
references.pmid: 12845330
references.citation: J Neurotrauma. 2004 Dec;21(12):1756-66
references.pmid: 15684767
references.citation: Neurol Res. 2006 Jun;28(4):381-98
references.pmid: 16759442
references.citation: Circulation. 1991 Sep;84(3):1216-34
references.pmid: 1909220
references.citation: J Neurosurg. 2005 Feb;102(2):194-201
references.pmid: 15739544
references.citation: Stroke. 2004 Aug;35(8):1862-6
references.pmid: 15218156
references.citation: Neurol Med Chir (Tokyo). 1990 May;30(5):309-16
references.pmid: 1699146
references.citation: J Neurosurg. 2005 Jun;102(6):1094-100
references.pmid: 16028769
references.citation: J Cereb Blood Flow Metab. 2007 Jul;27(7):1293-308
references.pmid: 17191079
references.citation: Neurology. 2000 Jan 11;54(1):77-82
references.pmid: 10636129
references.citation: Scand J Clin Lab Invest. 2002;62(3):195-9
references.pmid: 12088338
references.citation: Neurosurgery. 1999 Mar;44(3):487-93; discussion 493-4
references.pmid: 10069585
references.citation: J Natl Med Assoc. 2006 Apr;98(4):627-30
references.pmid: 16623076
references.citation: Stroke. 2008 Nov;39(11):3015-21
references.pmid: 18688013
references.citation: J Neurosurg. 1951 Nov;8(6):660-7
references.pmid: 14889314
references.citation: Stroke. 2007 Jun;38(6):1831-6
references.pmid: 17446425
references.citation: Zentralbl Neurochir. 2003;64(3):104-8
references.pmid: 12975744
references.citation: J Neurosurg. 2003 Dec;99(6):953-9
references.pmid: 14705720
references.citation: Blood. 2010 Jun 24;115(25):5241-8
references.pmid: 20410503
references.citation: Stroke. 1971 May-Jun;2(3):268-72
references.pmid: 5111575